Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4758376 | 0.88 | TSHR (0.32) | TSHR | |
| SCHEMBL5087631 | 0.78 | SMN1; SMN2 (0.42) | — | |
| SCHEMBL5088929 | 0.76 | MAOA (0.48) | — | |
| SCHEMBL29734626 | 0.76 | MAOA (0.48) | — | |
| SCHEMBL29734622 | 0.76 | MAOA (0.48) | — | |
| SCHEMBL4789470 | 0.75 | THRB (0.40) | TSHR | |
| SCHEMBL4758404 | 0.72 | SMN1; SMN2 (0.36) | TSHR | |
| SCHEMBL29734579 | 0.72 | SMN1; SMN2 (0.36) | TSHR | |
| SCHEMBL10794515 | 0.71 | THRB (0.35) | TSHR | |
| SCHEMBL5092633 | 0.71 | MTNR1A (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12492275-B2 | Photo-curable compositions containing high refractive index monomers for use in 3D printing applications | ARKEMA FRANCE (FR) | 2025-12-09 | — | — | US | claimed |
| US-20240052081-A1 | PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS | ARKEMA FRANCE (FR) | 2024-02-15 | — | — | US | claimed |
| EP-4028480-A1 | PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS | ARKEMA FRANCE (FR) | 2022-07-20 | — | — | EP | claimed |
| US-12492275-B2 | Photo-curable compositions containing high refractive index monomers for use in 3D printing applications | ARKEMA FRANCE (FR) | 2025-12-09 | — | — | US | disclosed |
| US-20240052081-A1 | PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS | ARKEMA FRANCE (FR) | 2024-02-15 | — | — | US | disclosed |
| EP-4028480-A1 | PHOTO-CURABLE COMPOSITIONS CONTAINING HIGH REFRACTIVE INDEX MONOMERS FOR USE IN 3D PRINTING APPLICATIONS | ARKEMA FRANCE (FR) | 2022-07-20 | — | — | EP | disclosed |
| US-20080145545-A1 | METAL OXIDE AND SULFUR-CONTAINING COATING COMPOSITIONS, METHODS OF USE, AND ARTICLES PREPARED THEREFROM | CITIBANK, N.A., AS COLLATERAL AGENT | 2008-06-19 | — | — | US | disclosed |
| US-7271283-B2 | High refractive index, UV-curable monomers and coating compositions prepared therefrom | GENERAL ELECTRIC COMPANY (US) | 2007-09-18 | — | — | US | disclosed |
| EP-1512704-A1 | High refractive index, UV-curable monomers and coating compositions prepared therefrom | GENERAL ELECTRIC COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | GENERAL ELECTRIC COMPANY | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049376-A1 | High refractive index, uv-curable monomers and coating compositions prepared therefrom | MACF1, WASF2, THEM6 | TSHR 4739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.